|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
127,470,000 |
Market
Cap: |
1.87(B) |
Last
Volume: |
637,170 |
Avg
Vol: |
1,050,354 |
52
Week Range: |
$11.665 - $20.73 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile NeoGenomics operate a network of cancer-focused testing laboratories in the U.S., Europe and Asia. Co.'s testing services include the following: Cytogenetics (karyotype analysis), a study of chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization, a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes; Flow cytometry, a technique utilized to measure the characteristics of cell populations; Immunohistochemistry and Digital Imaging; Molecular testing; and Morphologic analysis, a process of analyzing cells under the microscope.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
1,040 |
2,089 |
13,457 |
13,457 |
Total Sell Value |
$16,695 |
$33,206 |
$218,581 |
$218,581 |
Total People Sold |
1 |
1 |
2 |
2 |
Total Sell Transactions |
1 |
2 |
5 |
5 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Balliet Jennifer |
VP and Chief Culture Officer |
|
2019-05-03 |
4 |
S |
$22.74 |
$682,200 |
D/D |
(30,000) |
22,862 |
|
- |
|
Cardoza George |
President, Pharma Services |
|
2019-05-03 |
4 |
S |
$22.82 |
$3,461,246 |
D/D |
(151,676) |
300,831 |
|
- |
|
Balliet Jennifer |
VP and Chief Culture Officer |
|
2019-05-02 |
4 |
OE |
$7.15 |
$219,433 |
D/D |
30,000 |
52,862 |
|
- |
|
Shovlin Robert J. |
President, Clinical Services |
|
2019-05-02 |
4 |
S |
$22.14 |
$2,642,343 |
D/D |
(119,347) |
162,307 |
|
- |
|
Shovlin Robert J. |
President, Clinical Services |
|
2019-05-02 |
4 |
OE |
$7.15 |
$977,998 |
D/D |
133,333 |
281,654 |
|
- |
|
Cardoza George |
President, Pharma Services |
|
2019-05-02 |
4 |
OE |
$4.78 |
$956,000 |
D/D |
200,000 |
452,507 |
|
- |
|
Balliet Jennifer |
VP and Chief Culture Officer |
|
2019-03-04 |
4 |
S |
$19.09 |
$267,260 |
D/D |
(14,000) |
22,862 |
|
- |
|
Balliet Jennifer |
VP and Chief Culture Officer |
|
2019-03-04 |
4 |
OE |
$8.03 |
$112,420 |
D/D |
14,000 |
36,862 |
|
- |
|
Mckenzie Kathryn B |
Principal Accounting Officer |
|
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,273 |
2,273 |
|
- |
|
Bonello William |
Chief Strategy Officer |
|
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,735 |
6,735 |
|
- |
|
Weiss Lawrence Martin |
Chief Scientific Officer |
|
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,893 |
5,893 |
|
- |
|
Cardoza George |
President, Pharma Services |
|
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,418 |
252,507 |
|
- |
|
Shovlin Robert J. |
President, Clinical Services |
|
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,944 |
148,321 |
|
- |
|
Virag Sharon |
Chief Financial Officer |
|
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,944 |
10,944 |
|
- |
|
Van Oort Douglas M |
Chairman and CEO |
|
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
37,883 |
2,092,435 |
|
- |
|
Balliet Jennifer |
VP and Chief Culture Officer |
|
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,862 |
22,862 |
|
- |
|
Balliet Jennifer |
VP and Chief Culture Officer |
|
2019-02-28 |
4 |
S |
$19.57 |
$587,100 |
D/D |
(30,000) |
20,000 |
|
- |
|
Balliet Jennifer |
VP and Chief Culture Officer |
|
2019-02-28 |
4 |
OE |
$7.52 |
$230,700 |
D/D |
30,000 |
50,000 |
|
- |
|
Shovlin Robert J. |
President, Clinical Services |
|
2019-02-28 |
4 |
OE |
$7.15 |
$100,000 |
D/D |
13,986 |
137,377 |
|
- |
|
Shovlin Robert J. |
President, Clinical Services |
|
2019-02-27 |
4 |
S |
$19.23 |
$848,716 |
D/D |
(44,135) |
123,391 |
|
- |
|
Jones Steven C |
Executive Vice President |
|
2019-02-27 |
4 |
S |
$18.78 |
$5,387,378 |
I/I |
(285,252) |
150,000 |
|
- |
|
Cardoza George |
President, Pharma Services |
|
2019-02-27 |
4 |
OE |
$3.45 |
$103,500 |
D/D |
30,000 |
244,089 |
|
- |
|
Shovlin Robert J. |
President, Clinical Services |
|
2019-02-26 |
4 |
S |
$18.88 |
$2,678,676 |
D/D |
(141,879) |
167,526 |
|
- |
|
Shovlin Robert J. |
President, Clinical Services |
|
2019-02-26 |
4 |
OE |
$7.15 |
$1,354,667 |
D/D |
186,014 |
309,405 |
|
- |
|
Jones Steven C |
Executive Vice President |
|
2019-02-26 |
4 |
S |
$19.24 |
$281,365 |
I/I |
(14,621) |
47,657 |
|
- |
|
431 Records found
|
|
Page 11 of 18 |
|
|